Browsing Category

Molecular Diagnostics

Advanced Technology Laboratory, Molecular Diagnostics

Test Discontinuation: MTHFR C677T

MTHFR C677T [LAB7390], the methylenetetrahydrofolate reductase mutation analysis, is being discontinued as an obsolete test.

The American College of Medical Genetics (ACMG) and American College of Obstetricians and Gynecologists (ACOG) have determined that MTHFR C677T testing has minimal clinical utility. Current testing recommendations indicate that this test should not be ordered as part of a routine evaluation for thrombophilia or adverse pregnancy outcomes. Continue Reading

Molecular Diagnostics

Cystic Fibrosis (CF) Carrier Screen Discontinued

Effective February 1, 2022, the Cystic Fibrosis (CF) Carrier Screen test, which includes the 23 common variants for cystic fibrosis recommended by ACOG/ACMG, will be discontinued as an orderable test at Spectrum Health Laboratory.

The recommended replacement test is the Cystic Fibrosis Mutation Analysis (Test ID: CFP) offered by Mayo Clinic Laboratories, a 106-variant panel which includes the recommended 23 common variants.

Continue Reading

Advanced Technology Laboratory, Compliance & Safety, Education & Training, General Information, Main lab, Microbiology, Molecular Diagnostics, Test Utilization

REMINDER: Herpes Simplex Virus (HSV) PCR and HSV Culture Orders

As of January 13, 2020, the Spectrum Health Microbiology Laboratory will switch any viral culture orders placed on cutaneous or mucocutaneous lesion specimens to molecular PCR testing as the preferred diagnostic method.

Please refer to these documents for specimen collection information and appropriate ordering codes:

HSV PCR Epic Codes

HSV PCR Interface Codes

Continue Reading

Advanced Technology Laboratory, Molecular Diagnostics

Methods update on BCR-ABL1 t[9;22] RT-PCR testing

An updated BCR-ABL1 t[9;22] RT-PCR assay went live on Jan 31, 2018. The BCR-ABL major and minor fusion transcripts are measured and reported separately after this update. The quantities of BCR-ABL1 major breakpoints fusion transcripts (type e13a2 and/or e14a2) are detected by FDA approved QuantideX® qPCR BCR-ABL IS Kit and the result is calibrated and reported on the International Scale (%IS). The quantities of BCR-ABL minor fusion transcripts are detected by QuantideX qPCR BCR-ABL minor kit and the result is reported as BCR-ABL1 to ABL1 ratio (%). This update provides more precise and standard measurements of BCR-ABL fusion RNA and supports the consistency of patient care in t(9;22) positive CML patients during monitoring of treatment with Tyrosine Kinase Inhibitors (TKIs).

Questions may be directed to the Molecular Diagnostics Laboratory using the “Contact Us” link above.

Lab Catalog link: LAB3222022: BCR-ABL1 t[9;22] RT- PCR  

Advanced Technology Laboratory, Cytogenetics, Flow Cytometry, General Information, Molecular Diagnostics

Advanced Technology Laboratory plays an important role in Oncology

Spectrum Health Regional Laboratory (SHRL) was featured on EightWest on WOOD TV8 on Tuesday, August 30, 2016. Dr. Stephanie F. Williams, Division Chief of Spectrum Health Adult Bone and Marrow Transplant, and Kim Collison, Director of Laboratory Services, talk about the importance and benefits of having SHRL’s Advanced Technology Laboratory right here in West Michigan.

The Advanced Technology Laboratory is “extremely important, particularly for patients with certain cancers…”

“It helps us to diagnose the patients faster and more accurately; to follow the progress of their disease during the treatments that we give, and even at times to guide us in what is the best treatment for a patient…”

“Within 2 hours we had the answer. We did not have to send that specimen out to another laboratory in another state.”

-Stephanie F. Williams, MD, Division Chief, Spectrum Health Adult Bone and Marrow Transplant

Advanced Technology Laboratory, Cytogenetics, Molecular Diagnostics, Test Spotlight

Lung Cancer Mutation Analysis Panel provides targeted treatments for patients

The treatment of non-small cell lung adenocarcinoma has become more successful due to targeted treatments based on the molecular profile of a patient’s particular tumor. The Lung Cancer Mutation Analysis panel is now available for clinical testing at the Spectrum Health Advanced Technology Laboratories (ATL).  Continue Reading